Linked Life Data

11443164

Source:http://linkedlifedata.com/resource/pubmed/id/11443164

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-7-9
pubmed:abstractText
It is unclear whether high levels of antigen-specific islet antibodies [GADA (glutamic acid decarboxylase 65 antibodies) and IA2-ab (protein tyrosine phosphatase-like protein antibodies)] predict beta-cell failure in patients with onset of diabetes in adult age. Therefore, GADA and IA2-ab levels at the diagnosis of diabetes were related to fasting plasma C-peptide levels 5 yr later in 148 patients with diabetes onset in adult age (age at onset, 20-77 yr; median, 57 yr). Classical islet cell antibodies (ICA) were also determined. Complete beta-cell failure (undetectable fasting plasma C-peptide) was only present in 4 patients at diagnosis of diabetes, but in 21 patients 5 yr thereafter. At diagnosis, ICA were detected in 20 of 21 (95%) patients with beta-cell failure after 5 yr and in only 7 of 127 (5%) without, whereas GADA and/or IA2-ab (>97.5 percentile of healthy controls) were detected in all 21 (100%) with but also in 23 of 127 (18%) patients without beta-cell failure after 5 yr. Thus, ICA had a higher positive predictive value (74%) than GADA and/or IA2-ab (47%; P < 0.05). With high cutoff values for GADA and IA2-ab, however, GADA and/or IA2-ab were detected in 19 of 21 (90%) patients with beta-cell failure vs. only in 5 of 127 (4%) without, giving a positive predictive value of 79%. Slightly elevated GADA levels in IA2-ab-negative patients were associated with progressive but not complete beta-cell failure within the study period. Hence, high GADA and/or IA2-ab levels predict a future complete beta-cell failure, whereas low GADA levels predict slowly progressive beta-cell insufficiency.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0021-972X
pubmed:author
pubmed:issnType
Print
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3032-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11443164-Adult, pubmed-meshheading:11443164-Aged, pubmed-meshheading:11443164-Autoantibodies, pubmed-meshheading:11443164-C-Peptide, pubmed-meshheading:11443164-Diabetes Mellitus, Type 1, pubmed-meshheading:11443164-Fasting, pubmed-meshheading:11443164-Female, pubmed-meshheading:11443164-Glucagon, pubmed-meshheading:11443164-Glucose Tolerance Test, pubmed-meshheading:11443164-Glutamate Decarboxylase, pubmed-meshheading:11443164-Hemoglobin A, Glycosylated, pubmed-meshheading:11443164-Humans, pubmed-meshheading:11443164-Islets of Langerhans, pubmed-meshheading:11443164-Kinetics, pubmed-meshheading:11443164-Male, pubmed-meshheading:11443164-Membrane Proteins, pubmed-meshheading:11443164-Middle Aged, pubmed-meshheading:11443164-Nerve Tissue Proteins, pubmed-meshheading:11443164-Prospective Studies, pubmed-meshheading:11443164-ROC Curve, pubmed-meshheading:11443164-Sensitivity and Specificity
pubmed:year
2001
pubmed:articleTitle
High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age.
pubmed:affiliation
Department of Endocrinology, University of Lund, Malmö University Hospital, SE-205 02 Malmö, Sweden. Henrik.Borg@endo.mas.lu.se
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't